Chi-Med commences Phase I/II trial of HMPL-453 for solid tumours

Hutchison China MediTech (Chi-Med) has commenced a Phase I/II clinical trial of HMPL-453 in China for the treatment of solid tumours in patients carrying fibroblast growth factor receptor (FGFR) genetic alteration.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news